** Brokerage Guggenheim raises PT on drug developer Travere Therapeutics to $45 from $41
** New PT represents a 142% upside to the stock's Monday close
** TVTX's Filspari is an FDA-approved drug for the treatment of IgA nephropathy (IgAN), a type of disease where a protein called IgA builds up in the kidneys, causing inflammation
** On Monday, TVTX reported $50 mln in preliminary Filspari net product sales in 4Q 2024, which is "somewhat above investor expectations" of $45 mln, brokerage says
** Brokerage says it is "increasingly optimistic" about Filspari's potential in IgAN and its potential label expansion to Focal Segmental Glomerulosclerosis $(FSGS)$, a type of kidney disease, representing a $2 bln peak sales opportunity in the U.S.
** Brokerage forecasts annual U.S. Filspari sales for 2025 at $266 mln
** TVTX gained ~82 in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。